At a glance
ClinicalIndex Comparison RecordN/ACompleted· 52 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Consistency of Immunohistochemical Detecting Assays Using E1L3N and 22C3 Monoclonal Antibodies for Detection of PD-L1 Expression in NSCLC Patients: A Prospective CONFIDENCE Study
In Brief
An observational study for Non Small Cell Lung Cancer. Completed, enrolled 52 participants across 1 site.
Detailed Summary
Evaluated the correlation between the qualitative test results of Xiamen Aide PD-L1 antibody reagent (immunohistochemistry) and the efficacy of Keytruda single-agent therapy, and the research data is used to support the registration and marketing of the assessment reagent
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartAug 2018
Primary CompletionSep 2021
Study CompletionOct 2021
First PostedNov 2021
TodayJul 2026
First PostedNov 22, 2021
Enrollment StartAug 5, 2018
Primary CompletionSep 5, 2021
Study CompletionOct 1, 2021
TodayJul 1, 2026
Enrollment to primary: 3.1 yearsPosted 4.6 years ago